‘Surprising’ lack of benefit to adding palbociclib to endocrine therapy in early HR+/HER2– breast cancerDecember 13, 2021Metastatic Breast CancerBreast Cancer
The evolving HER2+ metastatic breast cancer landscape: Novel agents and promising combination therapiesDecember 11, 2021Breast CancerMetastatic Breast Cancer
Ongoing HER2 breast cancer therapy may cost an additional $68,000 per patientDecember 10, 2021Metastatic Breast CancerBreast Cancer
Vitamin D counters bone density loss with aromatase inhibitorsDecember 10, 2021Metastatic Breast CancerBreast Cancer
Metformin does not improve outcomes in early breast cancerDecember 10, 2021Metastatic Breast CancerBreast Cancer
Genomic profiling can improve PFS in metastatic breast cancerDecember 8, 2021Metastatic Breast CancerBreast Cancer
CDK4/6 inhibitors: Should they be stopped in the face of COVID-19?December 8, 2021Metastatic Breast Cancer
In metastatic breast cancer, primary resections on the declineDecember 8, 2021Metastatic Breast Cancer
Risk for breast cancer recurrence persists past 30 yearsNovember 18, 2021Metastatic Breast CancerBreast Cancer
Many breast cancer patients use cannabis for symptom reliefNovember 18, 2021Metastatic Breast CancerBreast Cancer
